Mylan Asks High Court To Review Generics Rulings

Law360, New York (December 14, 2010, 2:09 PM EST) -- Mylan Pharmaceuticals Inc. has asked the U.S. Supreme Court to review its loss in a patent infringement suit over generic hypertension drugs, claiming that a federal appeals court has established a “troubling pattern” of relying on a rigid test for obviousness in generics cases.

The generic drug maker filed its petition for certiorari Dec. 8, asking the high court to hear an appeal of the September decision by the U.S. Court of Appeals for the Federal Circuit that barred Mylan from making versions of Daiichi Sankyo...
To view the full article, register now.